Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03274479
Other study ID # PBF-1129CT_03
Secondary ID
Status Active, not recruiting
Phase Phase 1
First received
Last updated
Start date October 1, 2018
Est. completion date August 1, 2024

Study information

Verified date February 2024
Source Palobiofarma SL
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Phase I clinical trial in Eastern Cooperative Oncology Group (ECOG) 0-1 patients with locally advanced or metastatic NSCLC to evaluate safety and tolerability of the compound PBF-1129, an Adenosine A2b receptor antagonist. The phase I dose escalation will be conducted 3+3 method. Pharmacokinetic (PK) data will be also obtained.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 18
Est. completion date August 1, 2024
Est. primary completion date May 1, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Histological or cytological diagnosis of metastatic squamous or non-squamous NSCLC. - Life expectancy greater or equal to 3 months, as determined by the investigator -Patients must have progressed on the standard therapy, including platinum based - chemotherapy. Patients with epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), or ROS-1 mutations must have progressed on standard treatment options including EGFR, ALK, or ROS-1-directed therapies. - No limits to the prior lines of treatment - ECOG performance status of 0/1 - Measurable Disease by RECIST v1.1 - Age greater than 18 years. - Adequate bone marrow, renal and hepatic function: - Absolute neutrophil count (ANC) = 1500 /µL - White blood cell count (WBC) t = 2.5 x 109/L (2500/µL) - Lymphocyte count = 0.5 x 109/L (500/µL) - Platelet count = 100 x 109/L (100,000/µL) without transfusion - Hemoglobin = (9.0 g/dL) - patients may be transfused to meet this criterion. - Aspartate aminotransferase AST, alanine aminotransferase (ALT), and alkaline phosphatase (ALP) = 2.5 x upper limit of normal (ULN) - Serum bilirubin = 1.5 x ULN, with the exception of patients with known Gilbert disease: serum bilirubin level = 3 x ULN - Creatinine clearance >60 mL/min (calculated using the Cockcroft-Gault formula) or by 24-hours urine collection - Written informed consent and any locally-required authorization obtained from the subject prior to performing any protocol-related procedures, including screening evaluations - Subject is willing and able to comply with the protocol for the duration of the study Exclusion Criteria: - Participation in another clinical study with an investigational product during the last 4 weeks or 5 half-lives prior to starting on treatment. - Symptomatic and/or untreated or actively progressing central nervous system (CNS) metastases or leptomeningeal disease. Patients with a history of treated CNS metastases are eligible, provided that all of the following criteria are met: - The patient has not received stereotactic radiotherapy within 7 days prior to initiation of study treatment or whole-brain radiotherapy within 14 days prior to initiation of study treatment. - The patient has no ongoing requirement for corticosteroids as therapy for CNS disease. Anti-convulsant therapy at a stable dose is permitted. - Serious uncontrolled medical disorder or active infection that would impair the patient's ability to receive study treatment. - Concurrent use of other anticancer approved or investigational agents is not allowed. - Autoimmune disorder - Prior malignancy in past 2 years or as identified in Section 7.2 of this protocol - Active or prior documented autoimmune disease within the past 2 years. NOTE: Patients with vitiligo, Grave's disease, or psoriasis not requiring systemic treatment (within the past 2 years) are not excluded. - Patients receiving systemic steroids = 10mg/day of prednisone or the equivalent - Smoking (cigarettes, cigars or pipes) must be discontinued at least 7 days prior to initiating study drug administration; smoking cessation products (transdermal nicotine patches or chewing gum may be used. - Pregnancy or breastfeeding, or intention of becoming pregnant during the study. Female subjects must either be of non-reproductive potential or have a negative serum pregnancy test result within 14 days prior to initiation of study treatment

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
PBF-1129
PBF-1129 once a day by oral administration

Locations

Country Name City State
United States Division of medical Oncology A450B Starling Loving Hall Ohio City Ohio

Sponsors (2)

Lead Sponsor Collaborator
Palobiofarma SL Ohio State University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Maximum Tolerated Dose (MTD) of PBF-1129 The MTD evaluation will be based on the Dose-limiting Toxicity (DLT) of the treated Population, which includes all subjects who receive any dose of PBF-1129, and will include Adverse events (AEs), Serious Adverse events (SAEs), laboratory evaluations and electrocardiogram (ECG) results 28 days
Secondary Time to PBF-1129 peak concentration in plasma "Tmax" The parameter will be calculated from plasma samples collected at days 1 and 29 after drug administration.It will consist in the time (in minutes) to reach the maximum "PBF-1129" concentration in plasma samples of patients after oral administration of PBF-1129. days 1 and 29
Secondary Time to PBF-1129 peak concentration in plasma at steady state "Tmax,ss" The parameter will be calculated from plasma samples collected at days 1 and 29 after drug administration.
It will consist in the time (in minutes) to reach the maximum "PBF-1129" concentration in plasma samples of patients during a dosing interval at steady state.
days 1 and 29
Secondary PBF-1129 peak concentration in plasma "Cmax" The parameter will be calculated from plasma samples collected at days 1 and 29 after drug administration. It will consist in the maximum plasma concentration (ng/mL) of PBF-1129 observed after administration. days 1 and 29
Secondary PBF-1129 peak concentration in plasma at steady state"Cmax,ss" The parameter will be calculated from plasma samples collected at days 1 and 29 after drug administration.It will consist in the maximum plasma concentration (ng/mL) of PBF-1129 observed during a dosing interval at steady state. days 1 and 29
Secondary The area under PBF-1129 plasma concentration-time curve to infinite time "AUC(0-inf)" The parameter will be calculated from plasma samples collected at days 1 and 29 after drug administration.
It will consist in the area under the concentration-time curve from zero up to 8 with extrapolation of the terminal phase. "AUC(0-inf)" will be given in Amount·time/ volume units
days 1 and 29
Secondary The area under PBF-1129 plasma concentration-time curve up to time 't' "AUC(0-t)" The parameter will be calculated from plasma samples collected at days 1 and 29 after drug administration.It will consist in the area under the concentration-time curve from zero up to a definite time t. "AUC(0-t)" will be given in Amount·time/ volume units. days 1 and 29
Secondary The area under PBF-1129 plasma concentration-time curve over the dosing interval "AUC(0-t)" The parameter will be calculated from plasma samples collected at days 1 and 29 after drug administration. It will consist in the area under the concentration-time curve over the dosing interval. "AUC(0-t)" will be given in Amount·time/ volume units. days 1 and 29
Secondary PBF-1129 half-life in plasma " t½" The parameter will be calculated from plasma samples collected at days 1 and 29 after drug administration. It will consist in the terminal half-life of PBF-1129 in plasma. "t½" will be given in hours (h) days 1 and 29
Secondary Efficacy as measured by Objective response rate (ORR) ORR: Response and progression will be evaluated in this study using the new international criteria proposed by the revised Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1).ORR is defined as confirmed complete response (CR) or partial response (PR) based on modified RECIST v1.1. 2 years
Secondary Efficacy as measured by Disease control rate (DCR) The disease control rate (DCR) will be estimated considering the following variables:
Complete response (CR), Partial response (PR) and stable disease (SD) as described by Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1). These variables will be assessed based on Imaging-based evaluation methods as chest x-ray, conventional computed tomography (CT) and magnetic resonance imaging (MRI) that will be performed every 2 cycles of 28 days administration.
2 years
Secondary Efficacy as measured by duration of response (DoR) Duration of response (DoR) is defined as the duration from the first documentation of OR to the first documented disease progression or death due to any cause, whichever occurs first 2 years
Secondary Efficacy as measured by progression-free survival (PFS) Progression-free survival (PFS) will be measured from the start of treatment until the documentation of disease progression or death due to any cause, whichever occurs first. For subjects who are alive and progression-free at the time of data cut-off for analysis, PFS will be censored at the last tumor assessment date. 2 years
Secondary Efficacy as measured by overall survival (OS) Overall survival (OS) will be determined as the time from the start of treatment until death due to any cause. 2 years
See also
  Status Clinical Trial Phase
Completed NCT03037086 - Asia PDL1 Study Among NSCLC Patients N/A
Recruiting NCT05662670 - A Phase I/II Study of WJ13404 Monotherapy in Patients With Advanced or Mentastatic Non-Small Cell Lung Cancer Phase 1/Phase 2
Recruiting NCT03502850 - Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of ASK120067 in Locally Advanced and Metastatic Non Small Cell Lung Cancer Phase 1/Phase 2
Not yet recruiting NCT05990127 - A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer Phase 3
Active, not recruiting NCT03969823 - Whole Genomic Landscape of Advanced EGFR-mutant NSCLC N/A
Completed NCT04207775 - Real World Study in Locally Advanced or Metastatic NSCLC Patients, Progressed From First-line EGFR-TKI Therapy
Completed NCT05631678 - Drug-drug Interaction Study Beteewn ASK120067 and Rifampicin or Itraconazole Phase 1
Not yet recruiting NCT06461156 - A Study of HS-10504 in Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC) Phase 1
Active, not recruiting NCT04143607 - ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC Phase 3
Completed NCT03414814 - Osimertinib for NSCLC With EGFR Exon 20 Insertion Mutation Phase 2
Completed NCT04360915 - Assessing the Pharmacokinetics Effects of Food on ASK120067 in Single Oral Administration in Chinese Healthy Subjects Phase 1